The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help ...

The British government announced a multimillion dollar pharmaceutical partnership with Eli Lilly, including a trial that will ...

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and ...

Eli Lilly (LLY) is calling on companies that have been selling off-brand versions of its popular diabetes and weight-loss ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

The FDA resolved the shortage of Eli Lilly's tirzepatide, but may revisit allowing compounding pharmacies to make copies, ...

Eli Lilly And Co. (NYSE:LLY) is ramping up its legal campaign against the compounding companies temporarily allowed to make ...